ATE270291T1 - Antivirus wirkung und auflösung von 2- hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3- oxathiolane - Google Patents

Antivirus wirkung und auflösung von 2- hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3- oxathiolane

Info

Publication number
ATE270291T1
ATE270291T1 AT99203367T AT99203367T ATE270291T1 AT E270291 T1 ATE270291 T1 AT E270291T1 AT 99203367 T AT99203367 T AT 99203367T AT 99203367 T AT99203367 T AT 99203367T AT E270291 T1 ATE270291 T1 AT E270291T1
Authority
AT
Austria
Prior art keywords
oxathiolane
hydroxymethyl
fluorocytosine
dissolution
antivirus effect
Prior art date
Application number
AT99203367T
Other languages
English (en)
Inventor
Dennis C Liotta
Raymond F Schinazi
Woo-Baeg Choi
Original Assignee
Univ Emory
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35276919&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE270291(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US07/659,760 external-priority patent/US5210085A/en
Application filed by Univ Emory filed Critical Univ Emory
Application granted granted Critical
Publication of ATE270291T1 publication Critical patent/ATE270291T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D411/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D411/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
AT99203367T 1991-02-22 1992-02-20 Antivirus wirkung und auflösung von 2- hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3- oxathiolane ATE270291T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US07/659,760 US5210085A (en) 1990-02-01 1991-02-22 Method for the synthesis, compositions and use of 2'-deoxy-5-fluoro-3'-thiacytidine and related compounds
US73608991A 1991-07-26 1991-07-26
US83115392A 1992-02-12 1992-02-12

Publications (1)

Publication Number Publication Date
ATE270291T1 true ATE270291T1 (de) 2004-07-15

Family

ID=35276919

Family Applications (2)

Application Number Title Priority Date Filing Date
AT04076245T ATE469147T1 (de) 1991-02-22 1992-02-20 Antivirale wirkung und auflösung von 2- hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3- oxathiolanen
AT99203367T ATE270291T1 (de) 1991-02-22 1992-02-20 Antivirus wirkung und auflösung von 2- hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3- oxathiolane

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT04076245T ATE469147T1 (de) 1991-02-22 1992-02-20 Antivirale wirkung und auflösung von 2- hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3- oxathiolanen

Country Status (25)

Country Link
EP (3) EP0575482A1 (de)
JP (2) JP2901160B2 (de)
KR (1) KR0172590B1 (de)
CN (4) CN1037682C (de)
AT (2) ATE469147T1 (de)
AU (2) AU679649B2 (de)
BG (1) BG62053B1 (de)
BR (1) BR9205661A (de)
CA (2) CA2513440C (de)
CZ (1) CZ295074B6 (de)
DE (2) DE69233379T2 (de)
DK (2) DK1439177T3 (de)
ES (2) ES2345102T3 (de)
FI (2) FI114915B (de)
HK (1) HK1026419A1 (de)
HU (2) HU227823B1 (de)
IE (1) IE920545A1 (de)
IL (1) IL100965A (de)
MX (1) MX9200747A (de)
MY (1) MY114350A (de)
NO (3) NO312399B1 (de)
NZ (2) NZ250842A (de)
PT (1) PT100151B (de)
RO (2) RO122814B1 (de)
WO (1) WO1992014743A2 (de)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5466806A (en) * 1989-02-08 1995-11-14 Biochem Pharma Inc. Processes for preparing substituted 1,3-oxathiolanes with antiviral properties
US6175008B1 (en) 1988-04-11 2001-01-16 Biochem Pharma Inc. Processes for preparing substituted 1,3-oxathiolanes with antiviral properties
PT674634E (pt) * 1989-02-08 2003-09-30 Iaf Biochem Int Processos para preparar 1,3-oxatiolanos substituidos com propriedades antivirais
US6642245B1 (en) 1990-02-01 2003-11-04 Emory University Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane
US5728575A (en) * 1990-02-01 1998-03-17 Emory University Method of resolution of 1,3-oxathiolane nucleoside enantiomers
US6703396B1 (en) 1990-02-01 2004-03-09 Emory University Method of resolution and antiviral activity of 1,3-oxathiolane nuclesoside enantiomers
US5276151A (en) * 1990-02-01 1994-01-04 Emory University Method of synthesis of 1,3-dioxolane nucleosides
US5204466A (en) * 1990-02-01 1993-04-20 Emory University Method and compositions for the synthesis of bch-189 and related compounds
US5444063A (en) * 1990-12-05 1995-08-22 Emory University Enantiomerically pure β-D-dioxolane nucleosides with selective anti-Hepatitis B virus activity
IL100502A (en) * 1991-01-03 1995-12-08 Iaf Biochem Int PHARMACEUTICAL PREPARATIONS CONTAINING CIS-4-AMINO-1-) 2-HYDROXIMETHIL-1,3-OXETYOLEN-5-IL (-
US6812233B1 (en) 1991-03-06 2004-11-02 Emory University Therapeutic nucleosides
DE69232649T2 (de) * 1991-03-06 2002-11-28 Emory University, Atlanta Verwendung von 5-fluoro-2'-deoxy-3'-thiacytidin zur behandlung von hepatitis b
US5817667A (en) * 1991-04-17 1998-10-06 University Of Georgia Research Foudation Compounds and methods for the treatment of cancer
GB9110874D0 (en) * 1991-05-20 1991-07-10 Iaf Biochem Int Medicaments
ZA923641B (en) * 1991-05-21 1993-02-24 Iaf Biochem Int Processes for the diastereoselective synthesis of nucleosides
GB9116601D0 (en) * 1991-08-01 1991-09-18 Iaf Biochem Int 1,3-oxathiolane nucleoside analogues
US6177435B1 (en) 1992-05-13 2001-01-23 Glaxo Wellcome Inc. Therapeutic combinations
ES2138624T3 (es) * 1992-05-13 2000-01-16 Wellcome Found Combinaciones terapeuticas.
GB9226927D0 (en) * 1992-12-24 1993-02-17 Iaf Biochem Int Dideoxy nucleoside analogues
US5627160A (en) * 1993-05-25 1997-05-06 Yale University L-2',3'-dideoxy nucleoside analogs as anti-hepatitis B (HBV) and anti-HIV agents
TW374087B (en) * 1993-05-25 1999-11-11 Univ Yale L-2',3'-dideoxy nucleotide analogs as anti-hepatitis B(HBV) and anti-HIV agents
US20020120130A1 (en) 1993-09-10 2002-08-29 Gilles Gosselin 2' or 3' -deoxy and 2', 3' -dideoxy-beta-L-pentofuranonucleo-side compounds, method of preparation and application in therapy, especially as anti- viral agents
WO1995007086A1 (en) * 1993-09-10 1995-03-16 Emory University Nucleosides with anti-hepatitis b virus activity
GB9320316D0 (en) * 1993-10-01 1993-11-17 Smithkline Beecham Plc Pharmaceuticals
US5587362A (en) * 1994-01-28 1996-12-24 Univ. Of Ga Research Foundation L-nucleosides
IL115156A (en) 1994-09-06 2000-07-16 Univ Georgia Pharmaceutical compositions for the treatment of cancer comprising 1-(2-hydroxymethyl-1,3-dioxolan-4-yl) cytosines
US6391859B1 (en) 1995-01-27 2002-05-21 Emory University [5-Carboxamido or 5-fluoro]-[2′,3′-unsaturated or 3′-modified]-pyrimidine nucleosides
US5703058A (en) * 1995-01-27 1997-12-30 Emory University Compositions containing 5-fluoro-2',3'-didehydro-2',3'-dideoxycytidine or a mono-, di-, or triphosphate thereof and a second antiviral agent
US5808040A (en) * 1995-01-30 1998-09-15 Yale University L-nucleosides incorporated into polymeric structure for stabilization of oligonucleotides
US5869461A (en) * 1995-03-16 1999-02-09 Yale University Reducing toxicity of L-nucleosides with D-nucleosides
EP0831852B1 (de) 1995-06-07 2006-11-29 Emory University Nucleoside mit anti-hepatitis b virus wirksamkeit
BR9709939A (pt) 1996-06-25 1999-08-10 Glaxo Group Ltd Combinação formulação farmacêutica processo de tratamento de uma infecção por hiv em um animal infectado usos de éster tetraidro-3-furanila do ácido 3s[3r*(1r*,2s*)]-[-3-[[4-amino-fenil)sulfonil](2-metilprop ril)-amino]-2-hidroxi-1-fenilmetil)propil]-carbâmico de zidovudina e de (2r,cis)-4-amino-1-(2-hidroximetil-1,3-oxatiolan-5-il)-(1h)-pirimidin-2-ona e pacote para paciente
US5753789A (en) * 1996-07-26 1998-05-19 Yale University Oligonucleotides containing L-nucleosides
CN1196701C (zh) 1997-03-19 2005-04-13 埃莫里大学 1,3－氧硒戊环核苷的合成及抗人类免疫缺陷病毒和抗乙肝病毒活性
IT1290447B1 (it) * 1997-03-28 1998-12-03 Zambon Spa Derivati 1,3-ossatiolanici ad attivita' antivirale
JP2001518899A (ja) 1997-04-07 2001-10-16 トライアングル ファーマシューティカルズ，インコーポレイティド 他の抗ウイルス剤との組合せにおけるｍｋｃ−４４２の使用
WO1999037754A2 (en) * 1998-01-26 1999-07-29 Pharm-Eco Laboratories, Inc. Enzyme activated supports for enantiomeric separations
MXPA00008348A (es) 1998-02-25 2005-07-15 Univ Emory 2-fluronucleosidos.
EP1535921A1 (de) 1998-08-12 2005-06-01 Gilead Sciences, Inc. Verfahren zu Herstellung von 1,3-Oxathiolane Nukleosiden
US6979561B1 (en) 1998-10-09 2005-12-27 Gilead Sciences, Inc. Non-homogeneous systems for the resolution of enantiomeric mixtures
DK1140937T3 (da) 1998-12-23 2004-03-22 Shire Biochem Inc Antivirale nucleosid-analoger
KR100339786B1 (ko) * 1999-04-02 2002-06-07 안용현 라세미 혼합물 상태로 존재하는 뉴클레오시드로부터 거울상 이성질체의 분리 방법
EP1634888A3 (de) 1999-11-12 2007-11-21 Pharmasset, Inc. Synthese von 2'-Deoxy-L-Nukleosiden
US6436948B1 (en) 2000-03-03 2002-08-20 University Of Georgia Research Foundation Inc. Method for the treatment of psoriasis and genital warts
CA2308559C (en) 2000-05-16 2005-07-26 Brantford Chemicals Inc. 1,3-oxathiolan-5-ones useful in the production of antiviral nucleoside analogues
KR101195019B1 (ko) 2000-10-18 2012-10-29 파마셋 인코포레이티드 바이러스 감염 및 비정상적인 세포 증식의 치료를 위한 변형된 뉴클레오시드
US6828119B2 (en) * 2001-01-04 2004-12-07 Bristol Myers Squibb Company Enzymatic deprotection of amines and hydroxides
DE10104231A1 (de) 2001-01-31 2002-08-08 Consortium Elektrochem Ind Verfahren zur enzymatischen Herstellung von enantiomerenreinen 1,3-Dioxolan-4-on-Derivaten
AU2008202336B2 (en) * 2001-03-01 2011-11-10 Abbvie Inc. Polymorphic and other crystalline forms of cis-FTC
DK1389207T3 (da) * 2001-03-01 2006-04-18 Gilead Sciences Inc Polymorfe og andre krystallinske former af cis-FTC
CA2481572A1 (en) * 2002-04-12 2003-10-23 Achillion Pharmaceuticals, Inc. Method for synthesizing .beta.-l-5-fluoro-2',3'-dideoxy-2',3'-didehydrocytidine(.beta.-l-fd4c)
WO2004048590A1 (en) * 2002-11-18 2004-06-10 Shire Biochem Inc. Stereoselective process for the production of dioxolane nucleoside analogues
KR20090053867A (ko) 2003-01-14 2009-05-27 길리애드 사이언시즈, 인코포레이티드 복합 항바이러스 치료를 위한 조성물 및 방법
ITMI20030578A1 (it) * 2003-03-24 2004-09-25 Clariant Lsm Italia Spa Processo ed intermedi per la preparazione di emtricitabina
CN101142211B (zh) * 2005-03-14 2013-06-05 塞尔加拿大有限公司 制备光学活性顺式-2-羟甲基-4-(胞嘧啶-1’-基)-1,3-氧硫杂戊环或其药物可接受盐的工艺和方法
TWI471145B (zh) 2005-06-13 2015-02-01 Bristol Myers Squibb & Gilead Sciences Llc 單一式藥學劑量型
TWI375560B (en) 2005-06-13 2012-11-01 Gilead Sciences Inc Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same
EP2144604B1 (de) 2007-02-28 2011-09-21 Conatus Pharmaceuticals, Inc. Verfahren zur Behandlung von chronischer viraler Hepatitis C mithilfe von RO 113-0830
EP2514750B1 (de) 2007-06-18 2013-11-20 Sunshine Lake Pharma Co., Ltd Bromphenylsubstituierte Thiazolydihydropyrimidine
US8350030B2 (en) 2007-12-07 2013-01-08 Matrix Laboratories Limited Process for producing 5-fluoro-1-(2R, 5S)-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine
JPWO2009107692A1 (ja) * 2008-02-29 2011-07-07 株式会社カネカ ２’−水酸基が保護されたリボヌクレオシド誘導体およびその製造方法
EP2376514A2 (de) 2008-12-23 2011-10-19 Pharmasset, Inc. Nukleosidanaloga
EP2376088B1 (de) 2008-12-23 2017-02-22 Gilead Pharmasset LLC 6-O-Substituierte-2-Amino-Purin-Nukleosid-Phosphoramidate
TW201031675A (en) 2008-12-23 2010-09-01 Pharmasset Inc Synthesis of purine nucleosides
EP2377862A1 (de) 2010-03-29 2011-10-19 Esteve Química, S.A. Verfahren zur Gewinnung von Emtricitabin
UY33311A (es) 2010-03-31 2011-10-31 Pharmasset Inc Fosforamidatos de nucleosidos
CN106511357A (zh) 2010-11-19 2017-03-22 吉利德科学公司 包含利匹韦林HCl和富马酸替诺福韦酯的治疗组合物
AU2013257951A1 (en) 2012-05-11 2015-01-22 Akron Molecules Ag Use of compounds for the treatment of pain
US9227990B2 (en) 2012-10-29 2016-01-05 Cipla Limited Antiviral phosphonate analogues and process for preparation thereof
CN102911167B (zh) * 2012-11-09 2014-06-25 合肥工业大学 一种高光学纯度的核苷类中间体的制备方法
CN104059057A (zh) * 2014-01-03 2014-09-24 石家庄龙泽制药有限公司 拉米夫定杂质3-tu的制备方法
CN108285895B (zh) * 2018-01-26 2020-06-23 中国科学院南海海洋研究所 一种酯酶EstC11及其编码基因和应用
KR102069443B1 (ko) 2018-08-31 2020-01-22 (주)대한뷰티산업진흥원 울금, 비트 및 무 추출물을 포함하는 바이오셀룰로오스 및 이의 제조방법
WO2021209563A1 (en) 2020-04-16 2021-10-21 Som Innovation Biotech, S.A. Compounds for use in the treatment of viral infections by respiratory syndrome-related coronavirus
US20230271993A1 (en) * 2020-07-14 2023-08-31 Sichuan University 3-deoxy-2-ketoaldonic acid nitrogen-containing derivative, preparation method thereof, and use thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4914028A (en) * 1988-02-10 1990-04-03 Eli Lilly And Company Method of preparing beta-2',2'-difluoronucleosides
US5047407A (en) * 1989-02-08 1991-09-10 Iaf Biochem International, Inc. 2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties
US5204466A (en) * 1990-02-01 1993-04-20 Emory University Method and compositions for the synthesis of bch-189 and related compounds
AU8864191A (en) * 1990-11-13 1992-06-11 Biochem Pharma Inc. Substituted 1,3-oxathiolanes and substituted 1,3-dithiolanes with antiviral properties
DE69232649T2 (de) 1991-03-06 2002-11-28 Emory University, Atlanta Verwendung von 5-fluoro-2'-deoxy-3'-thiacytidin zur behandlung von hepatitis b

Also Published As

Publication number Publication date
AU3794395A (en) 1996-03-14
HU227823B1 (en) 2012-03-28
DE69233379D1 (de) 2004-08-05
MY114350A (en) 2002-10-31
ES2345102T3 (es) 2010-09-15
AU665187B2 (en) 1995-12-21
CN100396785C (zh) 2008-06-25
FI114915B (fi) 2005-01-31
NO932980L (no) 1993-08-20
AU1561792A (en) 1992-09-15
EP0984013B1 (de) 2004-06-30
EP1439177A1 (de) 2004-07-21
HU211344A9 (en) 1995-11-28
NZ250842A (en) 1996-03-26
IE920545A1 (en) 1992-08-26
CA2104399C (en) 2005-10-18
PT100151B (pt) 1999-09-30
PT100151A (pt) 1993-05-31
JPH06508605A (ja) 1994-09-29
ES2224547T3 (es) 2005-03-01
IL100965A (en) 1999-12-31
KR0172590B1 (ko) 1999-02-01
HK1026419A1 (en) 2000-12-15
NO932980D0 (no) 1993-08-20
HU9302377D0 (en) 1993-11-29
FI933684A0 (fi) 1993-08-20
EP0984013A2 (de) 2000-03-08
FI933684A (fi) 1993-09-06
JP3292830B2 (ja) 2002-06-17
CN1037682C (zh) 1998-03-11
CN1065065A (zh) 1992-10-07
HUT65548A (en) 1994-06-28
RO119365B1 (ro) 2004-08-30
AU8077398A (en) 1998-10-15
IL100965A0 (en) 1992-11-15
EP0575482A1 (de) 1993-12-29
DE69233379T2 (de) 2005-07-14
CA2513440A1 (en) 1992-09-03
WO1992014743A3 (en) 1992-10-29
CN1203232A (zh) 1998-12-30
BG62053B1 (bg) 1999-01-29
CN1084745C (zh) 2002-05-15
CN1109108C (zh) 2003-05-21
CZ49792A3 (en) 1993-03-17
EP1439177B1 (de) 2010-05-26
WO1992014743A2 (en) 1992-09-03
CN1127301A (zh) 1996-07-24
NO2005015I2 (no) 2007-10-01
EP0984013A3 (de) 2000-08-02
NO2008010I1 (no) 2008-07-07
BR9205661A (pt) 1994-05-24
BG98062A (bg) 1994-04-29
JP2901160B2 (ja) 1999-06-07
DK0984013T3 (da) 2004-10-25
CN1418966A (zh) 2003-05-21
NO2005015I1 (no) 2005-07-11
DE69233786D1 (de) 2010-07-08
ATE469147T1 (de) 2010-06-15
FI20030932A (fi) 2003-06-24
AU679649B2 (en) 1997-07-03
RO122814B1 (ro) 2010-02-26
NO312399B1 (no) 2002-05-06
DK1439177T3 (da) 2010-08-02
MX9200747A (es) 1992-09-01
NZ241625A (en) 1996-03-26
CA2104399A1 (en) 1992-08-23
JPH10147586A (ja) 1998-06-02
CZ295074B6 (cs) 2005-05-18
CA2513440C (en) 2010-11-30

Similar Documents

Publication Publication Date Title
ATE270291T1 (de) Antivirus wirkung und auflösung von 2- hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3- oxathiolane
RU94013464A (ru) Нуклеозидные аналоги 1,3-оксатиолана, способ получения, фармацевтическая композиция, способ лечения вирусной инфекции
YU74992A (sh) Postupak za pravljenje (-)4-amino-5-fluoro-1-(2-hidroksimetil-1,3-oksatiolan-5-il)-(1h)-pirimidin-2-ona
TW366346B (en) 1,3-oxathiolane nucleoside analogue
ATE138065T1 (de) Substituierte 1,3-oxathiolane mit antiviraler wirkung
MX9202374A (es) 1,3-oxatiolanos utiles en el tratamiento de hepatitis.
DE69233693D1 (de) Salze und Amide von (-) cis 5-Fluoro-2'-deoxy-3'-thiacytidine geeignet für die Behandlung von Hepatitis B
DE69525742D1 (de) Substituierte 1,3-oxathiolane mit antiviralen eigenschaften
ES2191659T3 (es) Derivados heterociclicos substituidos utiles como inhibidores de la agregacion plaquetaria.
ATE303154T1 (de) Verwendung von einem trifluridin derivat allein oder in kombination mit einem thymidin- phosphorylase-hemmer zur behandlung von hiv
ITMI931582A1 (it) Derivati del 2, 2, 6, 6-tetrametil-4-piperidinolo utili come stabilizzanti alla luce ed all'ossidazione per materiali organici.
EA199900757A1 (ru) Фармацевтические композиции
RU93058540A (ru) Производные 2-гидроксиметил-5-/5-фторцитозин-1-ил/-1,3-оксатиолан, фармкомпозиция, способы его получения, применение, способы лечения
DK0952157T3 (da) 9a, 11b-dehydroderivater af 9-oxim-3-keto-6-0-methylerythromycin
ES2116522T3 (es) Compuestos citotoxicos.
FI954183A (fi) Menetelmä valmistaa cis-4-amino-1-(2-hydroksimetyyli-1,3-oksatiolan-5-yyli)-(1H)-pyrimidin-2-onin (-)enantiomeeriä käytettäväksi virustenvastaisena aineena

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0984013

Country of ref document: EP